Regencell Bioscience Selected as Top 5 Best IPO Stocks on NASDAQ and New York Stock Exchange

[Asia Economy Reporter Park Ji-hwan] Regencell Bioscience, a Nasdaq-listed biotech company in the United States, announced on the 25th that it ranked in the top 5 among IPO companies on Nasdaq and the New York Stock Exchange (NYSE) last year, and top 3 in the healthcare sector IPO performance.

Regencell was established in 2014 and is headquartered in Hong Kong. It is an early-stage life sciences company focused on the research, development, and commercialization of traditional Chinese medicine for the treatment of neurocognitive disorders and degeneration, as well as infectious diseases that affect the human immune system.

Regencell recently completed its first human efficacy trial treating ADHD and ASD with TCM formulations in just three months, achieving average reductions of 37% and 30% in the Autism Treatment Evaluation Checklist (ATEC) and Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS) scores, respectively. The company is already conducting a second human efficacy trial, while many pharmaceutical and biotech companies spend from $100 million to over $1 billion on R&D before reaching Phase 1 clinical trials, continuing to invest billions despite low success rates.

Last year, Regencell achieved IPO performance ranking in the top 5 among a record 1,035 IPO companies on Nasdaq and NYSE, and top 3 in the healthcare sector. The company’s stock price surged approximately 321.05% from its trading debut on July 16 last year to February 17 this year. It also recorded an impressive increase of about 54.44% over the past three months.

Yat-Gai Au, founder and CEO of Regencell, said, "Because we aim to be the market leader providing 100% natural and comprehensive treatments for neurocognitive disorders and infectious diseases, we believe the company will deliver long-term and meaningful shareholder value over the coming years."

Regencell remains committed to saving and improving the lives of patients with ADHD, ASD, and COVID-19, their families, and caregivers, and to becoming the global market leader in treatments for ADHD, ASD, and COVID-19. In 2019, it successfully completed its first efficacy trial for ADHD and ASD treatment. The clinical trial liquid formulation RGC-COV19TM demonstrated approximately 97.3% effectiveness in eliminating mild to moderate COVID-19 symptoms within a 6-day treatment period in the holistic approach evaluation of RGC-COV19TM TCM.

This content was produced with the assistance of AI translation services.